I think the challenge with CARSS, although it's a very good initial step, is that it's not comprehensive and does not feel the pulse of all the places where health care is being delivered.
Not only do we need to know about teaching hospitals where there's a problem, but we also need to know where there's no problem so that we're not wasting resources where there is no problem. It's the Brandon versus Brampton argument that I made.
Speaking of antibiotic development, I cited a reference in my PowerPoint slides on the WHO pipeline. Without getting overly burdensome, there are a few promising drugs, but there is a discovery void, and one of the big problems for big pharma is that it is not cost-effective to develop a new antibiotic. What's really needed now are government-funded initiatives paired with pharma to make it financially viable to pursue a short course of therapy.
If you're a drug company, you want a drug that can hook people, like opioids. If you want a drug that really gets people hooked, you want them on it forever. You don't want them on it for just 10 days in a hospital. It's really hard to make it cost-effective unless you make it $10,000 for a course.
You need government funding from multiple countries' governments through global initiatives to bring new drug classes to market. TB is an ignored disease affecting people in developing countries who aren't going to pay the list price. It will be like what happened with hepatitis C drugs, so you need global funding initiatives. Just as we help with other UN agencies, we need to do our part in funding these drug development strategies in partnerships with pharma, rather than relying on pharma, because pharma is not going to do it.